Japan's Ono Pharma Licenses Heart Drug From France's Servier
This article was originally published in PharmAsia News
Executive Summary
Japan's Ono Pharmaceutical and Les Laboratoires Servier of France have signed a licensing agreement for developing and marketing a chronic heart-failure treatment in Japan